NATICK, Mass., Jan. 5 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced that it has completed enrollment in its MAPS(TM) clinical trial, which is studying the coiling of intracranial aneurysms. This prospective, randomized trial commenced enrollment in 2007 and has reached its goal of 630 patients, enrolled at 47 hospitals in 11 countries. Principal investigators for the trial are Anil Gholkar, O.B.E., M.B.B.S., Clay Johnston, M.D., Ph.D., and Cameron McDougall, M.D.
“The MAPS trial has significant potential to enhance our understanding of the products we use to treat intracranial aneurysms as well as our methods for assessing outcomes,” said Dr. Gholkar. “By conducting rigorous measurement, monitoring and adjudication of clinical outcomes over multiple years, the MAPS trial will establish a critical baseline from which to judge existing treatments as well as future endovascular technologies.”
“This important trial is the latest example of Boston Scientific’s 24 years of collaboration and leadership in the field of neurointervention and lays the groundwork for continued advances in the minimally invasive treatment of brain aneurysms,” said Mark Paul, President of Boston Scientific’s Neurovascular business. “We appreciate the participation of the 124 physicians and 63 research coordinators, whose efforts led to the successful completion of enrollment.”
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, clinical outcomes and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Boston Scientific Corporation
